Novel therapeutic strategies for treating Pseudomonas aeruginosa infection
Research output: Journal Publications and Reviews › RGC 21 - Publication in refereed journal › peer-review
Author(s)
Related Research Unit(s)
Detail(s)
| Original language | English |
|---|---|
| Pages (from-to) | 1403-1423 |
| Journal / Publication | Expert Opinion on Drug Discovery |
| Volume | 15 |
| Issue number | 12 |
| Online published | 3 Sept 2020 |
| Publication status | Published - 2020 |
Link(s)
Abstract
Introduction
Persistent infections caused by the superbug Pseudomonas aeruginosa and its resistance to multiple antimicrobial agents are huge threats to patients with cystic fibrosis as well as those with compromised immune systems. Multidrug-resistant P. aeruginosa has posed a major challenge to conventional antibiotics and therapeutic approaches, which show limited efficacy and cause serious side effects. The public demand for new antibiotics is enormous; yet, drug development pipelines have started to run dry with limited targets available for inventing new antibacterial drugs. Consequently, it is important to uncover potential therapeutic targets.
Areas covered
The authors review the current state of drug development strategies that are promising in terms of the development of novel and potent drugs to treat P. aeruginosa infection.
Expert opinion
The prevention of P. aeruginosa infection is increasingly challenging. Furthermore, targeting key virulence regulators has great potential for developing novel anti-P. aeruginosa drugs. Additional promising strategies include bacteriophage therapy, immunotherapies, and antimicrobial peptides. Additionally, the authors believe that in the coming years, the overall network of molecular regulatory mechanism of P. aeruginosa virulence will be fully elucidated, which will provide more novel and promising drug targets for treating P. aeruginosa infections.
Persistent infections caused by the superbug Pseudomonas aeruginosa and its resistance to multiple antimicrobial agents are huge threats to patients with cystic fibrosis as well as those with compromised immune systems. Multidrug-resistant P. aeruginosa has posed a major challenge to conventional antibiotics and therapeutic approaches, which show limited efficacy and cause serious side effects. The public demand for new antibiotics is enormous; yet, drug development pipelines have started to run dry with limited targets available for inventing new antibacterial drugs. Consequently, it is important to uncover potential therapeutic targets.
Areas covered
The authors review the current state of drug development strategies that are promising in terms of the development of novel and potent drugs to treat P. aeruginosa infection.
Expert opinion
The prevention of P. aeruginosa infection is increasingly challenging. Furthermore, targeting key virulence regulators has great potential for developing novel anti-P. aeruginosa drugs. Additional promising strategies include bacteriophage therapy, immunotherapies, and antimicrobial peptides. Additionally, the authors believe that in the coming years, the overall network of molecular regulatory mechanism of P. aeruginosa virulence will be fully elucidated, which will provide more novel and promising drug targets for treating P. aeruginosa infections.
Research Area(s)
- inhibitor, Pseudomonas aeruginosa, quorum sensing, transcriptional regulators, type III secretion system, type VI secretion system, virulence
Citation Format(s)
Novel therapeutic strategies for treating Pseudomonas aeruginosa infection. / Shao, Xiaolong; Xie, Yingpeng; Zhang, Yingchao et al.
In: Expert Opinion on Drug Discovery, Vol. 15, No. 12, 2020, p. 1403-1423 .
In: Expert Opinion on Drug Discovery, Vol. 15, No. 12, 2020, p. 1403-1423 .
Research output: Journal Publications and Reviews › RGC 21 - Publication in refereed journal › peer-review
